Bart Filius Buys 150,000 Shares of ProQR Therapeutics
Bart Filius purchased 150,000 shares of ProQR Therapeutics, boosting his stake significantly.
Key Points
- Bart Filius bought 150,000 shares of ProQR Therapeutics for $231,000 on June 26.
- ProQR Therapeutics, trading at $1.83, has a market cap of $161.2 million and a forward P/E of -2.25.
- Analysts maintain a strong buy rating with an average price target of $8.13 for ProQR Therapeutics.
Important disclosure: Podchat is not a registered investment adviser, broker-dealer, or financial planner. This article is for informational and educational purposes only and is not a recommendation to buy, sell, or hold any security. Content may be generated by automated systems using public filings, market data, and third-party sources, and may contain errors or omissions. Investing involves risk, including possible loss of principal. Past performance, insider activity, analyst ratings, price targets, sentiment scores, and hypothetical or backtested results are not guarantees of future performance. Please do your own research and consult a qualified professional before making investment decisions.
On June 26, 2026, Bart Filius purchased 150,000 shares of ProQR Therapeutics N.V. (NasdaqCM: PRQR) at an average price of $1.54 per share. This transaction, totaling $231,000, was not made under a pre-planned trading program.
Insider Buying and Selling at ProQR Therapeutics N.V.
Bart Filius's purchase was accompanied by other insider activity at ProQR Therapeutics. On June 2, Gylvin Lykke Hinsch also acquired shares, buying 14,595 and 14,495 shares in two separate transactions. Neither of these purchases was pre-planned, reinforcing the insiders' confidence in the company.
Other Institutional Activity in ProQR Therapeutics
In recent institutional activity, several funds adjusted their holdings in ProQR Therapeutics. Privium Fund Management B.V. grew its stake by 109,387 shares, bringing its total to 5,467,149 shares valued at approximately $8.86 million, marking a 2.0% increase. Aberdeen Group PLC increased its holdings by 366,289 shares, ending with 3,316,965 shares worth about $5.37 million, a 12.4% rise. On the other hand, Sio Capital Management, LLC reduced its position by 209,466 shares, now holding 1,954,715 shares valued at $3.17 million, reflecting a 9.7% decrease.
ProQR Therapeutics N.V. Stock Down 14.1%
Shares of ProQR Therapeutics traded near $1.83 on Wednesday. The company, with a market cap of $161.2 million, has a forward P/E ratio of -2.25, indicating it is not profitable at the moment. Its beta of 0.061 suggests low volatility compared to the market. The stock's 52-week range is between $1.33 and $3.10, with a 50-day moving average of $1.60 and a 200-day moving average of $1.90. ProQR maintains a current ratio of 2.48 and a quick ratio of 2.39, with a debt-to-equity ratio of 41.85.
$PRQR stock price
Daily closing prices, year to date. Not investment advice.
Analysts Set New Price Targets
Recently, analysts have maintained strong buy ratings for ProQR Therapeutics. On June 29, Evercore ISI Group maintained its buy rating with a $6.00 price target. Similarly, on June 26, Jones Trading reaffirmed its buy rating with a target of $10.00, and Chardan Capital maintained its buy rating with a $3.00 target. The consensus among analysts is a strong buy, with an average price target of $8.13.
About ProQR Therapeutics
ProQR Therapeutics N.V. is a biotechnology company based in Leiden, Netherlands, focused on developing RNA-based therapies for genetic disorders. Using its Axiomer RNA editing technology, the company targets unmet medical needs. Its lead candidate, AX-0810, aims to treat cholestatic diseases, while other products target conditions like Rett syndrome and cardiovascular diseases. ProQR collaborates with Eli Lilly on potential therapies for liver and nervous system disorders.
Bottom Line
Bart Filius's recent purchase of ProQR shares indicates insider confidence in the company's future. ProQR Therapeutics is a clinical-stage biotech firm with promising RNA-based therapies in development. Investors often track such insider activities and analyst ratings to gauge potential future performance, though it's important to remember this information reflects past transactions and opinions.
Get ProQR Therapeutics N.V. alerts
New 13F filings, insider trades, and analyst moves on $PRQR, sent to your inbox. Free, and you can unsubscribe anytime.
This instant news alert was generated by automated narrative technology and financial data from Podchat and public regulatory filings. It is for informational purposes only and is not financial advice.